NCT01465243View on ClinicalTrials.gov

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

February 28, 2014

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Icotinib

125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)

Trial Locations (1)

100071

307 Hospital of People's Liberation Army（PLA）, Beijing

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY